Risk and Benefit of Secondary Prevention with Aspirin Versus P2Y12 Inhibitor in CAD Patients
Clinical question: In patients with coronary artery disease (CAD), what is the difference in risk and benefit between secondary prevention with aspirin (ASA) versus a P2Y12 inhibitor?
Background: Lifelong ASA is the mainstay of care for patients with CAD who require secondary prevention. This is predicated on studies from several decades ago. Subsequent studies examining P2Y12 monotherapy versus ASA have had inconsistent results.
Study design: Systematic review and meta-analysis
Setting: Seven randomized clinical trials from 1996 to 2021 were found to meet the criteria for analysis.
Synopsis: 24,325 patients were included ...
Source: The Hospitalist - April 1, 2024 Category: Hospital Management Authors: Ronda Whitaker Tags: Cardiology In the Literature Source Type: research
Huanglian Jiedu decoction inhibits vascular smooth muscle cell-derived foam cell formation by activating autophagy via suppressing P2RY12
CONCLUSIONS: HLJDD inhibited AS in vivo and foam cell formation in vitro by restoring P2RY12/PI3K/AKT signaling pathway-suppressed autophagy. This study is the first to reveal an interaction between P2RY12 and PI3K3CB.PMID:38561055 | DOI:10.1016/j.jep.2024.118125 (Source: Atherosclerosis)
Source: Atherosclerosis - April 1, 2024 Category: Cardiology Authors: Jinhai Lin Mingyang Gu Xiaolong Wang Yuanyuan Chen Nhi Van Chau Junlong Li Qingmin Chu Lijin Qing Wei Wu Source Type: research
Safety of Clopidogrel vs. Ticagrelor in Dual Antiplatelet Therapy Regimens for High-Bleeding Risk Acute Coronary Syndrome Patients: A Comprehensive Meta-analysis of Adverse Outcomes
ConclusionBoth drugs are generally safe for treating ACS patients with HBR at baseline, although a higher risk of MI was observed with the use of clopidogrel. Nevertheless, drug choice should factor in regional variations, patient-specific characteristics, cost, accessibility, and potential drug interactions. (Source: High Blood Pressure and Cardiovascular Prevention)
Source: High Blood Pressure and Cardiovascular Prevention - April 1, 2024 Category: Cardiology Source Type: research
Low-dose prasugrel versus standard-dose ticagrelor in east Asian patients with acute coronary syndrome
This study included ACS patients who underwent percutaneous coronary intervention and, at discharge between January 1, 2018 and December 31, 2020, were prescribed with low-dose prasugrel plus aspirin or standard-dose ticagrelor plus aspirin. Stabilized inve rse probability of treatment weighting was used to balance the covariates across these two groups. The primary effectiveness outcome was a composite of acute myocardial infarction, ischemic stroke, and cardiovascular death; the secondary effectiveness outcome was each of the individual components of the primary outcome, transient ischemic attack, and repeat revasculariz...
Source: Journal of Thrombosis and Thrombolysis - March 31, 2024 Category: Hematology Source Type: research
Ticagrelor was associated with lower fracture risk than clopidogrel in the dual anti-platelet regimen among patients with acute coronary syndrome treated with percutaneous coronary intervention
ConclusionAmong adults who underwent first-ever PCI for ACS, ticagrelor use in the DAPT was associated with a lower risk of MOF compared with clopidogrel. Our results support the use of ticagrelor in the DAPT from the perspective of bone health. (Source: Journal of Endocrinological Investigation)
Source: Journal of Endocrinological Investigation - March 29, 2024 Category: Endocrinology Source Type: research
A woman with eptifibatide (integrilin) ‐induced thrombocytopenia following treatment of a clot in her coronary artery: A case report and literature review
AbstractEptifibatide, a GPIIb/IIIa receptor inhibitor, has shown its efficacy and safety in patients with high clot burden in their coronary vessels. It is widely used in patients with this condition. However, this medication use is accompanied by complications in some cases. Thrombocytopenia which is a relatively common condition in patients admitted to the hospital, especially in the acute setting, can be caused by medications. This condition can occur as an antibody or non-antibody-mediated process, caused by medications, such as heparin, clopidogrel, and eptifibatide. In this case, we present a woman with acute coronar...
Source: Clinical Case Reports - March 28, 2024 Category: General Medicine Authors: Morteza Safi,
Roozbeh Nazari,
Nahid Senobari,
Homa Taheri,
Pouya Ebrahimi Tags: CASE REPORT Source Type: research
Ticagrelor was associated with lower fracture risk than clopidogrel in the dual anti-platelet regimen among patients with acute coronary syndrome treated with percutaneous coronary intervention
ConclusionAmong adults who underwent first-ever PCI for ACS, ticagrelor use in the DAPT was associated with a lower risk of MOF compared with clopidogrel. Our results support the use of ticagrelor in the DAPT from the perspective of bone health. (Source: Journal of Endocrinological Investigation)
Source: Journal of Endocrinological Investigation - March 27, 2024 Category: Endocrinology Source Type: research
It's time to overcome the "One-Size-Fits-All" approach in chronic coronary syndrome?
Chronic coronary syndrome (CCS) refers to a wide spectrum of clinical conditions characterized by clinically stable progression of coronary artery disease (CAD) [1]. Current guidelines recommend the administration of dual antiplatelet therapy (DAPT) with cardioaspirin and clopidogrel for 6 months for patients undergoing elective percutaneous coronary intervention (PCI) [1]. However, patients with CCS represent a heterogeneous population and the type and duration of DAPT can be modulated weighting the individual ischemic and hemorrhagic risks [1]. (Source: The American Journal of Cardiology)
Source: The American Journal of Cardiology - March 27, 2024 Category: Cardiology Authors: Giampaolo Niccoli, Filippo Luca Gurgoglione Tags: Editorial Source Type: research
It Is Time to Overcome the “One-Size-Fits-All” Approach in Chronic Coronary Syndrome?
Chronic coronary syndrome (CCS) refers to a wide spectrum of clinical conditions characterized by clinically stable progression of coronary artery disease (CAD).1 Current guidelines recommend the administration of dual antiplatelet therapy (DAPT) with cardioaspirin and clopidogrel for 6 months for patients who underwent elective percutaneous coronary intervention (PCI).1 However, patients with CCS represent a heterogeneous population, and the type and duration of DAPT can be modulated weighting the individual ischemic and hemorrhagic risks. (Source: The American Journal of Cardiology)
Source: The American Journal of Cardiology - March 27, 2024 Category: Cardiology Authors: Giampaolo Niccoli, Filippo Luca Gurgoglione Tags: Editorial Source Type: research
